What is ClearPoint Neuro's restricted cash?

ClearPoint Neuro (CLPT) reported restricted cash of $923K in Q1 2026.

What does restricted cash mean?

Cash restricted for specific purposes by contractual, regulatory, or legal requirements — not available for general corporate use.

ClearPoint Neuro CLPT Restricted Cash

Restricted Cash at other companies

Orthofix Medical Inc.OFIX

$592K-76.3%

Neuropace, Inc.NPCE

$852K+598%

Ginkgo BioworksDNA

$6.88M-13.3%

MapLight Therapeutics, Inc. MPLT

$207K—

Boston ScientificBSX

——

Other financials

Income statement

See full

Revenue$12.1M+42.9%

Gross profit$7.8M+51.1%

Operating income-$8.5M-37.6%

Net income-$9.6M-58.5%

EPS (diluted)-$0.32-45.5%

Balance sheet

See full

Cash & equivalents$36.5M+195%

Total debt$63.6M+1,750%

Total equity$18.8M-5.7%

Total assets$93.4M+211%

Cash flow

See full

Operating cash flow-$8.0M-29.1%

CapEx$645.0K+252%

Free cash flow-$8.6M-35.5%

Valuation

See full

Market cap$538.61M+69.2%

Enterprise value$565.68M+82.9%

P/S13.3×+3.4×

Profitability

See full

Gross margin62.3%+1.1pp

Operating margin-65.2%-1.9pp

Net margin-71.6%+8.8pp

FCF margin-65.7%+269pp

Returns & leverage

See full

Return on equity-149.7%+4,074pp

Debt / equity3.4×+3.2×

Current ratio5.8×+2.3×

Where this comes from

Reported directly by ClearPoint Neuro in its filing.

Tagged under the XBRL concept us-gaap:RestrictedCash.

The official record: ClearPoint Neuro’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →

Ask your AI about ClearPoint Neuro's restricted cash.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is ClearPoint Neuro's restricted cash?: ClearPoint Neuro (CLPT) reported restricted cash of $923K in Q1 2026.
What does restricted cash mean?: Cash restricted for specific purposes by contractual, regulatory, or legal requirements — not available for general corporate use.